DCs and CD40-activated B cells: Current and future avenues to cellular cancer immunotherapy

Trends in Immunology

Volumn 25, Issue 12, 2004, Pages 659-664

  Schultze, Joachim L ^a   Grabbe, Stephan ^b   Von Bergwelt Baildon, Michael S ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD14 ANTIGEN; CD34 ANTIGEN; CD40 ANTIGEN; CHEMOKINE RECEPTOR CCR7; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA A ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 4; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN; PADGEM PROTEIN; TOLL LIKE RECEPTOR; TUMOR ANTIGEN;

ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; APOPTOSIS; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL DIFFERENTIATION; CELL MATURATION; CELL POPULATION; CELL PROLIFERATION; CELLULAR IMMUNITY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; ENDOCYTOSIS; HUMAN; MOLECULAR MECHANICS; MONOCYTE; NATURAL KILLER CELL; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; TH1 CELL; UPREGULATION; VACCINATION;

EID: 7644241044     PISSN: 14714906     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.it.2004.09.016     Document Type: Article

References (70)

1. F.J. Hsu Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells Nat. Med. 2 1996 52 58
2. D. Ridgway The first 1000 dendritic cell vaccines Cancer Invest. 21 2003 873 886
3. C.G. Figdor Dendritic cell immunotherapy: mapping the way Nat. Med. 10 2004 475 480
4. R.M. Steinman, and Z.A. Cohn Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution J. Exp. Med. 137 1973 1142 1162
5. G. Schuler The use of dendritic cells in cancer immunotherapy Curr. Opin. Immunol. 15 2003 138 147
6. B. Pulendran Sensing pathogens and tuning immune responses Science 293 2001 253 256
7. + progenitors J. Immunol. 164 2000 3600 3607
8. J. Banchereau Dendritic cells as vectors for therapy Cell 106 2001 271 274
9. I.J. De Vries Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state Cancer Res. 63 2003 12 17
10. T. Luft Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E(2) regulates the migratory capacity of specific DC subsets Blood 100 2002 1362 1372
11. E. Scandella Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells Blood 100 2002 1354 1361
12. S. Fujii Activation of natural killer T cells by α- galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein J. Exp. Med. 198 2003 267 279
13. + T lymphocyte responses by dendritic cells armed with PSA/anti-PSA (antigen-antibody) complexes Clin. Immunol. 101 2001 276 283
14. Y. Nagata Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations Proc. Natl. Acad. Sci. U. S. A. 99 2002 10629 10634
15. M.V. Dhodapkar T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells Proc. Natl. Acad. Sci. U. S. A. 99 2002 13009 13013
16. A. Engering The dendritic cell-specific adhesion receptor DC-SIGN internalizes antigen for presentation to T cells J. Immunol. 168 2002 2118 2126
17. J.J. Campbell 6-C-kine (SLC), a lymphocyte adhesion-triggering chemokine expressed by high endothelium, is an agonist for the MIP-3β receptor CCR7 J. Cell Biol. 141 1998 1053 1059
18. R.A. Warnock Molecular mechanisms of lymphocyte homing to peripheral lymph nodes J. Exp. Med. 187 1998 205 216
19. U.H. von Andrian, and T.R. Mempel Homing and cellular traffic in lymph nodes Nat. Rev. Immunol. 3 2003 867 878
20. A. Martin-Fontecha Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming J. Exp. Med. 198 2003 615 621
21. A.F. Ochsenbein Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction Nature 411 2001 1058 1064
22. H. Jonuleit A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection Int. J. Cancer 93 2001 243 251
23. G. Ratzinger Matrix metalloproteinases 9 and 2 are necessary for the migration of Langerhans cells and dermal dendritic cells from human and murine skin J. Immunol. 168 2002 4361 4371
24. C. Robert Gene therapy to target dendritic cells from blood to lymph nodes Gene Ther. 10 2003 1479 1486
25. L. Fong Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy Proc. Natl. Acad. Sci. U. S. A. 98 2001 8809 8814
26. B. Thurner Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma J. Exp. Med. 190 1999 1669 1678
27. L. Fong Dendritic cells injected via different routes induce immunity in cancer patients J. Immunol. 166 2001 4254 4259
28. F.O. Nestle Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells Nat. Med. 4 1998 328 332
29. B. Ludewig Dendritic cells induce autoimmune diabetes and maintain disease via de novo formation of local lymphoid tissue J. Exp. Med. 188 1998 1493 1501
30. + T-cell in humans without foreign helper epitopes J. Clin. Invest. 105 2000 R9 R14
31. M. Gilliet Intranodal injection of semimature monocyte-derived dendritic cells induces T helper type 1 responses to protein neoantigen Blood 102 2003 36 42
32. P. Brossart Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells Blood 96 2000 3102 3108
33. + progenitor-derived dendritic cell vaccine Cancer Res. 61 2001 6451 6458
34. M.G. O'Rourke Durable complete clinical responses in a Phase I/II trial using an autologous melanoma cell/dendritic cell vaccine Cancer Immunol. Immunother. 52 2003 387 395
35. J.M. Timmerman Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients Blood 99 2002 1517 1526
36. L. Holtl Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells Clin. Cancer Res. 8 2002 3369 3376
37. L. Fong Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy J. Immunol. 167 2001 7150 7156
38. A. Heiser Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors J. Clin. Invest. 109 2002 409 417
39. F.D. Finkelman Dendritic cells can present antigen in vivo in a tolerogenic or immunogenic fashion J. Immunol. 157 1996 1406 1414
40. H. Hackstein Designer dendritic cells for tolerance induction: guided not misguided missiles Trends Immunol. 22 2001 437 442
41. K. Shortman, and Y.J. Liu Mouse and human dendritic cell subtypes Nat. Rev. Immunol. 2 2002 151 161
42. A.K. Thomas A cell-based artificial antigen-presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and long-term growth of CD4 T lymphocytes Clin. Immunol. 105 2002 259 272
43. M.V. Maus Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB Nat. Biotechnol. 20 2002 143 148
44. J.B. Latouche, and M. Sadelain Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells Nat. Biotechnol. 18 2000 405 409
45. G.A. Papanicolaou Rapid expansion of cytomegalovirus-specific cytotoxic T lymphocytes by artificial antigen-presenting cells expressing a single HLA allele Blood 102 2003 2498 2505
46. J.L. Schultze CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy J. Clin. Invest. 100 1997 2757 2765
47. E.E. Eynon, and D.C. Parker Small B cells as antigen-presenting cells in the induction of tolerance to soluble protein antigens J. Exp. Med. 175 1992 131 138
48. + T cells J. Exp. Med. 188 1998 1977 1983
49. Z. Qin B cells inhibit induction of T cell-dependent tumor immunity Nat. Med. 4 1998 627 630
50. M.J. Mamula, and C.A. Janeway Jr Do B cells drive the diversification of immune responses? Immunol. Today 14 1993 151 152
51. A.I. Jaiswal, and M. Croft CD40 ligand induction on T cell subsets by peptide-presenting B cells: implications for development of the primary T and B cell response J. Immunol. 159 1997 2282 2291
52. Y.J. Liu Memory B cells from human tonsils colonize mucosal epithelium and directly present antigen to T cells by rapid up-regulation of B7-1 and B7-2 Immunity 2 1995 239 248
53. M. Croft Partial activation of naive CD4 T cells and tolerance induction in response to peptide presented by resting B cells J. Immunol. 159 1997 3257 3265
54. + T cells to protein antigens in vivo J. Immunol. 155 1995 3734 3741
55. J.L. Schultze Human non-germinal center B cell interleukin (IL)-12 production is primarily regulated by T cell signals CD40 ligand, interferon gamma, and IL-10: role of B cells in the maintenance of T cell responses J. Exp. Med. 189 1999 1 12
56. D. Verthelyi, and R.A. Zeuner Differential signaling by CpG DNA in DCs and B cells: not just TLR9 Trends Immunol. 24 2003 519 522
57. C. Arpin Generation of memory B cells and plasma cells in vitro Science 268 1995 720 722
58. C. van Kooten, and J. Banchereau Functions of CD40 on B cells, dendritic cells and other cells Curr. Opin. Immunol. 9 1997 330 337
59. R. Lapointe CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells Cancer Res. 63 2003 2836 2843
60. R. Lapointe Reply to Correspondence to von Bergwelt-Baildon et al. CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells Cancer Res. 64 2004 4056 4057
61. M. von Bergwelt-Baildon CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells Cancer Res. 64 2004 4055 4056
62. X. Chen Regulated expression of human histocompatibility leukocyte antigen (HLA)-DO during antigen-dependent and antigen-independent phases of B cell development J. Exp. Med. 195 2002 1053 1062
63. K.S. Glazier Germinal center B cells regulate their capability to present antigen by modulation of HLA-DO J. Exp. Med. 195 2002 1063 1069
64. M.S. von Bergwelt-Baildon Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application Blood 99 2002 3319 3325
65. E. Kondo Efficient generation of antigen-specific cytotoxic T cells using retrovirally transduced CD40-activated B cells J. Immunol. 169 2002 2164 2171
66. E. Kondo Identification of novel CTL epitopes of CMV-pp65 presented by a variety of HLA alleles Blood 103 2004 630 638
67. C.M. Coughlin RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy Blood 103 2004 2046 2054
68. F.O. Nestle Dendritic cells: On the move from bench to bedside Nat. Med. 7 2001 761 765
69. FDA (1998) Guidance for human somatic cell therapy and gene therapy. (Vol. 1998) U.S. Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research (www.fda.gov)
70. ICH (1996) ICH Topic E6 Guideline for Good Clinical Practice. (Vol. 1996) EMEA, Inspections, 7 Westferry Circus, Canary Wharf, London E14 4HB (www.emea.eu.int/pdfs/human/ich/013595en.pdf)